Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiwan Announces $1.9 Billion Mega Fund To Nurture Biotech Industry

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Taiwan's push to do with the biotech sector what it did with IT two decades ago will be anchored on a $1.9 billion "mega fund" unveiled earlier this month

You may also be interested in...



Taiwan Biotech Touts Drug Derived From Chinese Medicine To Treat Cancer Patients

Taiwan’s Maywufa Bio Pharmaceutical Group launched a cancer-related fatigue treatment derived from an herb used in traditional Chinese medicine and plans to investigate it for cardiovascular use with clinical trials in the United States.

China And Taiwan Move Toward Clinical Data Mutual Acceptance, Regulatory Harmonization

China and Taiwan's top health regulators have signed an agreement to harmonize clinical and non-clinical studies toward mutual data acceptance. The deal could open doors for more Taiwanese drugs in the Chinese market, industry experts say

China And Taiwan Move Toward Clinical Data Mutual Acceptance, Regulatory Harmonization

China and Taiwan's top health regulators have signed an agreement to harmonize clinical and non-clinical studies toward mutual data acceptance. The deal could open doors for more Taiwanese drugs in the Chinese market, industry experts say

Related Content

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel